VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | The safety and efficacy of elotuzumab for the treatment of multiple myeloma

In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the safety and efficacy of elotuzumab for the treatment of multiple myeloma, drawing focus on updated results from the SWOG-1211 trial (NCT01668719). Dr Richardson comments on the encouraging survival data observed with the addition of elotuzumab to bortezomib, lenalidomide and dexamethasone (RVd), and further emphasizes the tolerability of this combination. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter